Answers are grounded in this paper and cite their sources.
This study evaluated the cytoprotective effects of osthole in SH-SY5Y cells exposed to 6-hydroxydopamine and explored potential molecular interactions relevant to Parkinson’s disease. Cells were pretreated with osthole (25–500 µM) before exposure to 200 µM 6-hydroxydopamine, followed by assessment of cell viability using the tetrazolium reduction assay and measurement of oxidative stress markers. Osthole significantly improved cell viability, reduced malondialdehyde levels, increased superoxide dismutase and catalase activities, and restored reduced glutathione levels compared with 6-hydroxydopamine alone. The highest mean values were observed at 250 µM, although the differences between concentrations were not statistically significant. Complementary molecular docking identified osthole as a predicted multi-target candidate, with docking scores of −6.0, −7.3, and −6.9 kcal/mol for neuritin 1, parkin, and tyrosine hydroxylase, respectively. Pharmacokinetic predictions suggested high intestinal absorption and potential blood–brain barrier penetration, although borderline central nervous system permeability and possible inhibition of the cytochrome P450 isoforms 1A2 and 2C19 were identified. These findings support the cytoprotective and antioxidant effects of osthole in this cellular model. The predicted protein interactions require target-specific experimental validation to determine whether they contribute to the observed cellular effects.
No takes yet. Share an insight, caveat, or question.
Erguney et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: